

## UC Irvine

### UC Irvine Previously Published Works

**Title**

Receptor-dependent formation of endogenous cannabinoids in cortical neurons

**Permalink**

<https://escholarship.org/uc/item/8743g3sm>

**Journal**

European Journal of Pharmacology, 425(3)

**ISSN**

0014-2999

**Authors**

Stella, Nephi  
Piomelli, Daniele

**Publication Date**

2001-08-01

**DOI**

10.1016/s0014-2999(01)01182-7

**Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

# Receptor-dependent formation of endogenous cannabinoids in cortical neurons

Nephi Stella<sup>1</sup>, Daniele Piomelli\*

Department of Pharmacology, 360 Med Surge II, University of California, Irvine, CA 92697-4625, USA

Received 17 May 2001; received in revised form 27 June 2001; accepted 3 July 2001

## Abstract

We investigated the transduction mechanisms mediating formation of the endogenous cannabinoid (endocannabinoid) lipids, anandamide (arachidonylethanolamide) and 2-arachidonylglycerol, in primary cultures of rat cortical neurons. Unstimulated neurons contained  $0.3 \pm 0.1$  pmol of anandamide and  $16.5 \pm 3.3$  pmol of 2-arachidonylglycerol per mg of protein, as determined by gas chromatography/mass spectrometry.  $\text{Ca}^{2+}$  entry into the neurons via activated glutamate *N*-methyl-D-aspartate (NMDA) receptors increased 2-arachidonylglycerol levels approximately three times, but had no effect on anandamide levels. By contrast, anandamide formation was stimulated five times by simultaneous activation of NMDA and acetylcholine receptors. Alone, acetylcholine receptor activation had no effect on anandamide or 2-arachidonylglycerol levels. The formation of fatty acid ethanolamides that do not activate cannabinoid receptors, including palmitylethanolamide and oleylethanolamide, was stimulated by coactivation of NMDA and acetylcholine receptors. Pharmacological experiments suggest that the cholinergic contribution to anandamide formation was mediated by  $\alpha 7$  nicotinic receptors (antagonized by methyllycaconitine), whereas the contribution to palmitylethanolamide and oleylethanolamide formation was mediated by muscarinic receptors (antagonized by atropine). These findings indicate that cortical neurons produce anandamide and 2-arachidonylglycerol in a receptor-dependent manner, and that brain neurons may generate different endocannabinoid lipids depending on their complement of neurotransmitter receptors. © 2001 Elsevier Science B.V. All rights reserved.

**Keywords:** Anandamide; Fatty acid ethanolamide; 2-Arachidonylglycerol; Glutamate; Acetylcholine

## 1. Introduction

Cannabinoid receptors, the molecular target for the psychoactive constituent of *Cannabis*  $\Delta^9$ -tetrahydrocannabinol (Piomelli et al., 2000), are activated by a family of lipid molecules that primarily include anandamide (arachidonylethanolamide) (Devane et al., 1992; Di Marzo et al., 1994) and 2-arachidonylglycerol (Mechoulam et al., 1995; Sugiura et al., 1995; Stella et al., 1997). Both anandamide and 2-arachidonylglycerol are produced by brain neurons in an activity-dependent manner (Di Marzo et al., 1994; Stella et al., 1997; Giuffrida et al., 1999), bind to and activate cannabinoid  $\text{CB}_1$  receptors (Felder et al., 1993; Vogel et al., 1993; Mechoulam et al., 1995; Sugiura et al., 1996), and undergo rapid biological inactivation (Di Marzo et al., 1994; Beltramo et al., 1997), suggesting that

they may act as endogenous modulatory substances (Piomelli et al., 2000).

Unlike classical neurotransmitters, the endogenous cannabinoids (endocannabinoids) may be produced upon demand by enzymatic cleavage of membrane lipid precursors and immediately extruded from neurons without an intermediate step of vesicle storage (Piomelli et al., 2000; Schmid, 2000). This feature—unusual in a brain chemical transmitter, but reminiscent of other lipid-derived mediators—prompted the two questions addressed in the present study. The first is how formation of anandamide and 2-arachidonylglycerol is initiated: is it stimulated by action potentials invading the synaptic nerve endings or by receptor-activated mechanisms? Previous studies have shown that anandamide and 2-arachidonylglycerol can be produced during neural activity *in vitro* and *in vivo*, but they have not investigated the cellular mechanisms of this response (Di Marzo et al., 1994; Stella et al., 1997; Giuffrida et al., 1999). The second question is whether, regardless of the mechanism involved, anandamide and 2-arachidonylglycerol can be generated independently of each other. An affirmative answer to this question would

\* Corresponding author. Tel.: +1-949-824-6180; fax: +1-949-824-6305.

E-mail address: piomelli@uci.edu (D. Piomelli).

<sup>1</sup> Present address: Department of Pharmacology, University of Washington, Seattle, WA 98195-7280, USA.

imply that these compounds may be released under different circumstances and, possibly, serve distinct functional roles in neuronal signaling. To begin to address these questions, we have investigated the mechanisms of anandamide and 2-arachidonylglycerol formation in primary cultures of rat brain cortical neurons. The results of our experiments show that anandamide and 2-arachidonylglycerol are produced in a receptor-dependent manner, and that segregated molecular mechanisms may underlie the formation of each of these compounds.

## 2. Materials and methods

### 2.1. Drugs

All drugs were purchased from Research Biochemical (Natick, MA) or Sigma (Saint Louis, MO).

### 2.2. Cell cultures

Cortical neurons were prepared as described (Brewer, 1995; Evans et al., 1998), with few modifications. Cerebral cortices were dissected from 18-day-old Wistar rat embryos and the neurons were dissociated mechanically. The neurons ( $10^6$  cells/ml) were then plated on 90-mm Corning® culture dishes (12.5 ml/dish) coated with poly-(L)-ornithine (10  $\mu$ g/ml; molecular weight: 30,000–70,000) and poly-(DL)-lysine (100  $\mu$ g/ml; molecular weight: 30,000–70,000). The culture medium was composed of B27-supplemented Neurobasal® containing 500  $\mu$ M L-glutamine, 24  $\mu$ M L-glutamic acid, 5  $\mu$ g/ml streptomycin and 10 U/ml penicillin. The neurons were maintained at 37 °C in a humidified atmosphere of 95% air and 5% CO<sub>2</sub>. After 3 days, 6 ml of the cell culture media were replaced with 7 ml of B27-supplemented Neurobasal® containing 500  $\mu$ M L-glutamine, 5  $\mu$ g/ml streptomycin and 10 U/ml penicillin.

### 2.3. Cell incubations

In preliminary experiments designed to study the kinetic of endogenous cannabinoid production, we labeled the neurons by overnight incubation with [<sup>14</sup>C]arachidonic acid and determined the time-course of [<sup>14</sup>C]2-arachidonylglycerol formation in the presence of glutamate (300  $\mu$ M) and/or carbachol (1 mM) (Stella et al., 1997). At the end of various incubation periods (0.5 to 15 min), lipids were extracted and analyzed by thin-layer chromatography (Stella et al., 1997). Glutamate significantly increased radioactivity in the 2-arachidonylglycerol fraction at 2.5 min ( $130 \pm 6\%$  of basal,  $n = 6$ ), whereas carbachol had no effect. Coapplication of glutamate and carbachol resulted in a greater [<sup>14</sup>C]2-arachidonylglycerol accumulation, which reached a maximum of  $192 \pm 6\%$  of basal at 2.5 min and lasted for at least 15 min ( $146 \pm 16\%$  of basal). Therefore,

we selected a 2.5-min incubation time for subsequent gas chromatography/mass spectrometry analyses. After 5–6 days in vitro, the incubation medium was removed and the neurons were washed twice in HEPES-bicarbonate buffer (9 ml, 15 min each) composed of (mM): NaCl, 120; KCl, 5.0; CaCl<sub>2</sub>, 2.0; MgSO<sub>4</sub>, 1.0; NaH<sub>2</sub>PO<sub>4</sub>, 1.0; Glucose, 10; NaHCO<sub>3</sub>, 5.0; and HEPES, 20 (pH 7.4 at 37 °C). Incubations were started by adding 1 ml of buffer containing drugs at 10 times their final concentration, and by gently shaking the culture dishes for 10 s to allow the drugs to diffuse uniformly. Neurons from two culture dishes were combined for each experimental point ( $1.17 \pm 0.03$  mg of protein/dish,  $n = 33$ ).

### 2.4. Lipid analyses

Incubations were stopped by adding 10 ml of ice-cold methanol. Cells were immediately scraped on ice and the supernatants were transferred into ice-cold chloroform (20 ml) that contained internal standards (0.6 nmol of each [<sup>2</sup>H<sub>4</sub>]acylethanolamide and 0.5 nmol of [<sup>2</sup>H<sub>8</sub>]2-arachidonylglycerol). This rapid procedure significantly reduced the non-enzymatic conversion of 2-arachidonylglycerol into 1(3)-arachidonylglycerol, yielding  $\approx 90\%$  2-arachidonylglycerol. Organic phases of duplicate samples were pooled, evaporated to dryness under N<sub>2</sub> gas, recovered in chloroform (2 ml), filtered through Ultra-free CL filters (Waters), and evaporated again. Lipids were reconstituted in chloroform (100  $\mu$ l) for high-performance liquid chromatography (HPLC) fractionation and gas chromatography/mass spectrometry analysis, which were carried out as described (Giuffrida and Piomelli, 1998).

## 3. Results

### 3.1. Anandamide formation via coactivation of N-methyl-D-aspartate (NMDA) and acetylcholine receptors

We used isotope dilution gas chromatography/mass spectrometry to investigate anandamide biosynthesis in rat cortical neurons in primary culture (Giuffrida and Piomelli, 1998). Fig. 1A shows the ion current trace obtained after analysis of a lipid fraction purified from these cells. A diagnostic component of mass-to-charge ratio ( $m/z$ ) 404 (the fragment produced from the molecular ion by loss of one methyl group), eluted from the column at the retention time of authentic standard, confirming that unstimulated neurons contain detectable levels of anandamide (Di Marzo et al., 1994; Cadas et al., 1997). Under basal conditions, we measured on average  $0.3 \pm 0.1$  pmol of anandamide per mg of protein, with values ranging from 0.1 to 1.35 pmol per mg of protein ( $n = 17$ ). This variability appeared to reflect differences amongst culture preparations, rather than within a single preparation, and might result from subtle inequalities in neuronal maturation under the




Fig. 1. Coactivation of glutamate NMDA and acetylcholine  $\alpha 7$  nicotinic receptors elicits anandamide formation in rat cortical neurons. (A) Identification of anandamide by selected ion monitoring gas chromatography/mass spectrometry. Anandamide was purified from neurons by HPLC and analyzed by gas chromatography/mass spectrometry as the trimethylsilylether (TMS) derivative. The fragment monitored was produced from the anandamide-TMS molecular ion by the loss of methyl group ( $[M-15]^+$ ,  $m/z$  404). The arrow indicates the retention time of standard anandamide. (B) Effects of glutamate and carbachol on anandamide levels. Neurons were incubated for 2.5 min in the presence of glutamate (glut, 300  $\mu$ M), carbachol (Cch, 1 mM), veratridine (10  $\mu$ M), and/or NMDA (300  $\mu$ M); in the presence of 100  $\mu$ M D-serine (Johnson and Ascher, 1987), and in the absence of extracellular magnesium (Nowak et al., 1984). \*  $P < 0.05$  and \*\*  $P < 0.01$  significantly different from basal (ANOVA followed by Dunnett's test). (C) Effects of various receptor antagonists on anandamide production. Neurons were pre-incubated for 30 min in buffer (control), or in buffer containing one of the following drugs: MK801 (1  $\mu$ M), DNQX (10  $\mu$ M), dihydro- $\beta$ -erythroidine ( $\beta$ -erythro, 10  $\mu$ M), methyllycaconitine (MLA, 30 nM) or atropine (1  $\mu$ M); and then incubated for 2.5 min with buffer (basal) or glutamate (300  $\mu$ M) plus carbachol (1 mM) (glut + Cch). \*  $P < 0.05$  and \*\*  $P < 0.01$  significantly different from basal (unpaired Student's  $t$ -test). (D) Effects of tetrodotoxin (TTX), pertussis toxin (PTX) and treatments that affect intracellular  $Ca^{2+}$  on anandamide production. Neurons were pre-incubated for 30 min in the presence of buffer (control), tetrodotoxin (TTX, 1  $\mu$ M), EGTA (1 mM; in the absence of  $Ca^{2+}$ ), BAPTA-AM (10  $\mu$ M), cadmium chloride ( $Cd^{2+}$ , 100  $\mu$ M), or treated for 18 h with pertussis toxin (PTX, 1  $\mu$ g/ml). Neurons were incubated for 2.5 min in buffer (basal) or in buffer containing glutamate (300  $\mu$ M) plus carbachol (1 mM) (glut + Cch). \*  $P < 0.05$  and \*\*  $P < 0.01$  significantly different from basal (unpaired Student's  $t$ -test). Results represent the mean  $\pm$  S.E.M. of 3–17 experiments.

serum-free culture conditions of these experiments. To limit the impact of variability on data interpretation, all treatment groups were compared to appropriate controls within the same cell culture preparation.

To determine whether activation of neurotransmitter receptors increased anandamide levels, we incubated the neurons for 2.5 min with glutamate (300  $\mu$ M) or carbachol, an acetylcholine receptor agonist (1 mM). Although these agents had no effect separately, they stimulated anandamide formation more than 5 times when applied together (Fig. 1B). Three pharmacological experiments suggest that anandamide biosynthesis resulted from the concomitant activation of glutamate NMDA and cholinergic  $\alpha 7$  nicotinic receptors. First, the combination NMDA (300  $\mu$ M)/carbachol was more effective at stimulating anandamide production than glutamate/carbachol (Fig. 1B). Second, the NMDA receptor antagonist dizocilpine (MK801, 1  $\mu$ M), but not the amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate (AMPA/kainate) receptor antagonist 6,7-dinitroquinoxaline-2,3 dione (DNQX, 10  $\mu$ M), prevented anandamide formation (Fig. 1C). Fi-

nally, the  $\alpha 7$  nicotinic receptor antagonist methyllycaconitine (30 nM) (Alkondon et al., 1992) blocked the response, whereas dihydro- $\beta$ -erythroidine (a nicotinic receptor antagonist that does not affect  $\alpha 7$  nicotinic receptors, 1  $\mu$ M) or atropine (a muscarinic receptor antagonist, 1  $\mu$ M) had no effect (Fig. 1C). Pretreatment of cells with pertussis toxin (1  $\mu$ g/ml, overnight) was also ineffective, which is consistent with a lack of  $G_{i/o}$  protein involvement (Fig. 1D).

Veratridine (10  $\mu$ M), a  $Na^+$  channel activator, did not increase anandamide levels in neurons (Fig. 1B) although it elevated intracellular  $Ca^{2+}$  in a cadmium-sensitive manner, as assessed by  $Ca^{2+}$  imaging (N. Stella and D. Piomelli, unpublished results). However, receptor-dependent anandamide production was significantly reduced by the  $Na^+$  channel blocker tetrodotoxin (1  $\mu$ M) (Fig. 1D). Together, these results suggest that activation of voltage-gated  $Na^+$  channels is necessary, but not sufficient to stimulate anandamide biosynthesis. Buffering intracellular  $Ca^{2+}$  with 1,2-bis(2-aminophenoxy)ethane- $N,N,N',N'$ -tetraacetic acid (acetoxymethyl) ester (BAPTA-AM, 10  $\mu$ M) prevented anandamide formation, whereas removal of ex-

ternal  $\text{Ca}^{2+}$  with EGTA (1 mM) or addition of cadmium chloride (100  $\mu\text{M}$ ) to block voltage-activated  $\text{Ca}^{2+}$  channels had no effect (Fig. 1D). Thus, NMDA and  $\alpha 7$  nicotinic receptors may act synergistically to evoke anandamide biosynthesis via a tetrodotoxin-sensitive mechanism that requires mobilization of  $\text{Ca}^{2+}$  from intracellular stores.

### 3.2. Production of other fatty acid ethanolamides

In cortical neurons, activity-dependent hydrolysis of saturated and monounsaturated species of *N*-acyl phosphatidylethanolamine generates several fatty acid ethanolamides in addition to anandamide (Di Marzo et al., 1994; Cadas et al., 1997; Hansen et al., 1997; Schmid, 2000). These compounds, of which palmitylethanolamide and oleylethanolamide are two prominent examples, do not activate cannabinoid receptors and have no established signaling function (Piomelli et al., 1998). Incubating the neurons with glutamate plus carbachol, not glutamate or carbachol alone, stimulated the formation of both palmitylethanolamide and oleylethanolamide (Figs. 2A,B and 3A,B). This response was mediated in all likelihood by co-activation of NMDA receptors and muscarinic receptors because, (i) NMDA was as effective as glutamate in eliciting palmitylethanolamide and oleylethanolamide production (Figs. 2B and 3B); (ii) MK801 and atropine blocked the response (Figs. 2C and 3C), whereas (iii) methyllycaconitine and dihydro- $\beta$ -erythroidine had no ef-

fect (Figs. 2C and 3C). Pertussis toxin had no significant effect on palmitylethanolamide and oleylethanolamide formation (Figs. 2D and 3D). Additional experiments will be necessary to determine the G protein coupling of the putative muscarinic receptor involved in this response. Receptor-dependent biosynthesis of palmitylethanolamide and oleylethanolamide was not affected by tetrodotoxin or by removal of external  $\text{Ca}^{2+}$  with EGTA, but was blocked by chelating intracellular  $\text{Ca}^{2+}$  with BAPTA-AM (Figs. 2D and 3D). The results indicate that coactivation of NMDA and muscarinic receptors stimulates palmitylethanolamide and oleylethanolamide formation by mobilizing  $\text{Ca}^{2+}$  ions from intracellular stores.

### 3.3. 2-Arachidonylglycerol formation via NMDA receptor-mediated $\text{Ca}^{2+}$ entry

To quantify 2-arachidonylglycerol in cortical neurons, we developed an isotope dilution gas chromatography/mass spectrometry assay similar to that used for anandamide. The electron-impact mass spectra of synthetic unlabeled and [ $^2\text{H}_8$ ]-labeled 2-arachidonylglycerol (analyzed as *bis* trimethylsilylether derivatives) included the molecular ions ( $[\text{M}]^+$ ,  $m/z$  530), and ions produced by loss of one methyl group ( $[\text{M}-15]^+$ ,  $m/z$  515) or one derivatizing trimethylsilylenol group ( $[\text{M}-90]^+$ ,  $m/z$  440). We monitored the  $[\text{M}-90]^+$  fragments, because of their reasonable abundance and high diagnostic value: rectilinear mass spectrometry responses ( $r^2 > 0.99$ ) were obtained with these fragments when amounts of synthetic




Fig. 2. Formation of palmitylethanolamide in cortical neurons. Experiments were carried out as described in Fig. 1 legend. (A) Identification of palmitylethanolamide by selected ion monitoring gas chromatography/mass spectrometry ( $m/z$  356,  $[\text{M}-15]^+$ ). The arrow indicates the retention time of standard palmitylethanolamide (PEA). (B) Effects of glutamate and carbachol on palmitylethanolamide levels. (C) Effects of various receptor antagonists on palmitylethanolamide production. (D) Effects of tetrodotoxin (TTX), pertussis toxin (PTX) and treatments that affect intracellular  $\text{Ca}^{2+}$  on palmitylethanolamide.




Fig. 3. Formation of oleylethanolamide in cortical neurons. Experiments were carried out as described in Fig. 1 legend. (A) Identification of oleylethanolamide by selected-ion monitoring gas chromatography/mass spectrometry ( $m/z$  382,  $[M-15]^+$ ). The arrow indicates the retention time of standard oleylethanolamide (OEA). (B) Effects of glutamate and carbachol on oleylethanolamide levels. (C) Effects of various receptor antagonists on oleylethanolamide production. (D) Effects of tetrodotoxin (TTX), pertussis toxin (PTX) and treatments that affect intracellular  $Ca^{2+}$  on oleylethanolamide production.

2-arachidonylglycerol ranging from 0 to 1 nmol were injected into gas chromatography/mass spectrometry together with a fixed amount of  $[^2H_8]$ 2-arachidonylglycerol (1 nmol).

Cortical neurons contained, on average,  $16.5 \pm 3.3$  pmol of 2-arachidonylglycerol per mg of protein ( $n = 17$ ). In these analyses, only a minor peak was detectable at the retention time of 1(3)-arachidonylglycerol (Fig. 4A), a




Fig. 4. NMDA receptor activation stimulates 2-arachidonylglycerol formation. Experiments were carried out as described in Fig. 1 legend. (A) Identification of 2-arachidonylglycerol by selected ion monitoring gas chromatography/mass spectrometry ( $m/z$  432,  $[M-90]^+$ ). The arrows indicate the retention times of standard 2-arachidonylglycerol (2-AG) and 1(3)-arachidonylglycerol (1(3)-AG). (B) Effects of glutamate and carbachol on 2-arachidonylglycerol levels. (C) Effects of various receptor antagonists on 2-arachidonylglycerol production. (D) Effects of tetrodotoxin (TTX), pertussis toxin (PTX) and treatments that affect intracellular  $Ca^{2+}$  on 2-arachidonylglycerol production.

compound that originates from the non-enzymatic isomerization of 2-arachidonylglycerol (Serdarevich, 1967; Mechoulam et al., 1995; Bisogno et al., 1997; Stella et al., 1997). 2-Arachidonylglycerol isomerization to 1(3)-arachidonylglycerol is typically fairly high (Stella et al., 1997), and its limited occurrence in the present experiments was probably due to the rapid extraction procedure utilized (see Materials and methods).

Three main features distinguished the mechanisms governing the receptor-dependent formation of 2-arachidonylglycerol from that of anandamide. First, activation of NMDA receptors was sufficient to cause a marked accumulation of 2-arachidonylglycerol in neurons (Fig. 4B). The application of glutamate or NMDA increased 2-arachidonylglycerol production about three times (Fig. 4B), and MK801 completely prevented this effect (Fig. 4C). DNQX partially impaired 2-arachidonylglycerol production, indicating that AMPA/kainate receptors may also be involved (Fig. 4C). Second, carbachol had little effect on 2-arachidonylglycerol biosynthesis when applied alone or in combination with glutamate, albeit it enhanced the effect of NMDA (Fig. 4B). The pharmacological basis of this enhancement was not investigated. Third, incubation with a medium containing the  $\text{Ca}^{2+}$  chelator EGTA abolished 2-arachidonylglycerol formation, whereas depleting internal  $\text{Ca}^{2+}$  with BAPTA-AM had no effect (Fig. 4D). The results suggest that flux of external  $\text{Ca}^{2+}$  allowed by the activation of ionotropic NMDA receptor channels is sufficient to elicit 2-arachidonylglycerol formation in cortical neurons.

#### 4. Discussion

Despite their similar chemical structures, anandamide and 2-arachidonylglycerol are produced through distinct biochemical pathways. Formation of anandamide may result from hydrolysis of the phospholipid precursor *N*-arachidonyl phosphatidylethanolamine, catalyzed by a phosphodiesterase such as phospholipase D (Di Marzo et al., 1994; Cadas et al., 1997; Schmid, 2000). 2-Arachidonylglycerol, on the other hand, may be produced by cleavage of 1,2-diacylglycerol generated by phospholipase C acting on phosphatidylinositol biphosphate (Gammon et al., 1989; Stella et al., 1997), although the participation of alternative pathways cannot be excluded (Piomelli et al., 2000). The existence of different enzymatic routes for the formation of anandamide and 2-arachidonylglycerol suggests that under certain circumstances, these two endocannabinoid substances might operate independently of each other. This possibility is supported by two findings. In hippocampal slices, stimulation of glutamate-releasing fibers in the Schaffer collaterals increases the levels of 2-arachidonylglycerol, but not those of anandamide (Stella et al., 1997). Conversely, in vivo microdialysis experiments show that activation of striatal  $\text{D}_2$ -family dopamine

receptors enhances release of anandamide, but not of 2-arachidonylglycerol (Giuffrida et al., 1999). It is unclear, however, whether this discrepancy reflects different experimental conditions, regional segregation of the phospholipase C and phospholipase D pathways, or receptor-activated mechanisms linked to the generation of specific endocannabinoid lipids. To examine these different possibilities, in the present study we have investigated the receptor mechanisms underlying the formation of anandamide and 2-arachidonylglycerol in primary cultures of rat cortical neurons.

Our findings indicate that the excitatory neurotransmitter glutamate triggers 2-arachidonylglycerol biosynthesis by allowing external  $\text{Ca}^{2+}$  to enter cortical neurons through activated NMDA receptor channels. In these cells, 2-arachidonylglycerol formation is likely to be mediated by the phospholipase C/diacylglycerol lipase pathway, because selective drug inhibitors of these enzyme activities prevent the accumulation of 2-arachidonylglycerol elicited by a  $\text{Ca}^{2+}$  ionophore (Stella et al., 1997). This conclusion is also in agreement with previous work showing that NMDA receptor activation stimulates phospholipase C and diacylglycerol lipase activities in cultured neurons (Nicolletti et al., 1986; Farooqui et al., 1993). Noteworthy, we found that activation of acetylcholine receptors with carbachol had little or no effect, per se, on 2-arachidonylglycerol levels. This result, at variance with the ability of cholinergic agonists to stimulate phospholipase C activity in many tissues and to cause 2-arachidonylglycerol accumulation in vascular endothelium (Mechoulam et al., 1998), underscores the differences in 2-arachidonylglycerol biosynthesis between neurons and other non-neuronal cell types.

The functional role of 2-arachidonylglycerol formation in NMDA receptor signaling is unclear at present. However, experiments with superfused hippocampal slices suggest that 2-arachidonylglycerol may act as a localized feedback signal within the hippocampus (Stella et al., 1997). Electrical stimulation of the Schaffer's collaterals, a glutamatergic fiber tract that projects from CA3 to CA1 neurons, produced a marked increase in 2-arachidonylglycerol accumulation in the slices, which was prevented by the  $\text{Na}^+$  channel blocker tetrodotoxin or by removal of external  $\text{Ca}^{2+}$  (Stella et al., 1997). In the same preparation, exogenous 2-arachidonylglycerol inhibited the induction of long-term potentiation at CA3–CA1 synapses by activating local cannabinoid  $\text{CB}_1$  receptors, whereas it had no effect on basal synaptic transmission (Stella et al., 1997). The possible role of 2-arachidonylglycerol as a negative feedback regulator of *N*-methyl-D-aspartate-mediated responses, suggested by these results, is reinforced by the ability of cannabinoid drugs to reduce glutamate transmission (Shen et al., 1996; Shen and Thayer, 1999), inhibit long-term potentiation (Collins et al., 1994; Terranova et al., 1995; Misner and Sullivan, 1999), and alleviate glutamate-induced neurotoxicity (Nagayama et al., 1999).

In the present experiments, the simultaneous application of glutamate and carbachol, but not of either agent alone, caused a marked stimulation of anandamide biosynthesis in cortical neurons. Pharmacological experiments suggest that this synergistic effect may result from the coactivation of NMDA and  $\alpha 7$  nicotinic receptors, and may depend both on membrane depolarization and on mobilization of  $\text{Ca}^{2+}$  ions from intracellular stores. Though necessary for the response, membrane depolarization was insufficient per se to initiate anandamide biosynthesis. This observation appears to contradict previous results, which showed that membrane-depolarizing agents increase accumulation of radioactive fatty acid ethanolamides in neuronal cultures maintained in a serum-containing medium and labeled with [ $^3\text{H}$ ]ethanolamine (Di Marzo et al., 1994; Cadas et al., 1996). Differences in cell culture models may provide, however, a plausible explanation for this discrepancy: neurons cultured in the presence of serum actively release neurotransmitters when they are challenged with membrane-depolarizing agents, whereas neuronal cultures maintained in a defined medium, such as those used in the present experiments, do not (Pfrieger and Barres, 1997; Evans et al., 1998). Thus, fatty acid ethanolamide biosynthesis in the former cultures might result, not from a direct effect of membrane depolarization, but from the action of neurotransmitters released in the extracellular medium. A similar indirect mechanism may be responsible for the release of anandamide induced in vivo by a depolarizing concentration of KCl, administered in dorsal striatum by reverse dialysis (Giuffrida et al., 1999).

Receptor-dependent anandamide formation may be distinguished pharmacologically from that of other fatty acid ethanolamides that do not activate cannabinoid receptors. Indeed, though biosynthesis of all fatty acid ethanolamides is contingent on NMDA receptor occupation, anandamide formation requires the coactivation of NMDA and  $\alpha 7$  nicotinic receptors, while oleylethanolamide and palmitylethanolamide formation requires the coactivation of NMDA and muscarinic receptors. Thus, glutamate and acetylcholine may elicit the biosynthesis of different fatty acid ethanolamides, depending on the complement of acetylcholine receptors expressed in their target neurons. The finding that palmitylethanolamide and oleylethanolamide may be produced by dissimilar molecular mechanisms and may exert biological effects that are not mediated by cannabinoid receptors (Calignano et al., 1998; Jaggar et al., 1998) raises the possibility that they might serve signaling functions independent from those of anandamide. Testing this possibility will require a thorough investigation of the pharmacological effects of palmitylethanolamide and oleylethanolamide in neurons, as well as the identification of the putative cellular targets that may mediate these effects.

In conclusion, biosynthesis of anandamide and 2-arachidonoylglycerol in cortical neurons may be triggered by activation of membrane receptors for the neurotrans-

mitters, glutamate and acetylcholine. This suggests that a key function of the endocannabinoid system in the brain may be to modulate the effects of primary neurotransmitters by a localized feedback action. In agreement with this idea, recent electrophysiological experiments have suggested that endocannabinoid compounds may serve as retrograde messengers in both hippocampus and cerebellum (Kreitzer and Regerh, 2001; Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). Finally, the finding that anandamide and 2-arachidonoylglycerol may be produced through divergent molecular mechanisms indicates that these two endocannabinoid lipids may exert their modulatory effects in separate and possibly complementary ways.

### Acknowledgements

We thank Drs. Andrea Giuffrida, Felice Nava and Fernando Rodríguez de Fonseca for their critical reading of the manuscript, Mr. Fernando Valiño for editorial assistance, and Dr. John Bradly for his help with the veratridine calcium imaging experiments. Support from the National Institute of Drug Abuse (under grant number 12447, to D.P.) and the Tourette Syndrome Association is gratefully acknowledged.

### References

- Alkondon, M., Pereira, E.F., Wonnacott, S., Albuquerque, E.X., 1992. Blockade of nicotinic currents in hippocampal neurons defines methyllycaconitine as a potent and specific receptor antagonist. *Mol. Pharmacol.* 41, 802–808.
- Beltramo, M., Stella, N., Calignano, A., Lin, S.Y., Makriyannis, A., Piomelli, D., 1997. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. *Science* 277, 1094–1097.
- Bisogno, T., Sepe, N., Melck, D., Maurelli, S., De Petrocellis, L., Di Marzo, V., 1997. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. *Biochem. J.* 322, 671–677.
- Brewer, G.J., 1995. Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus. *J. Neurosci. Res.* 42, 674–683.
- Cadas, H., Gaillet, S., Beltramo, M., Venance, L., Piomelli, D., 1996. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. *J. Neurosci.* 16, 3934–3942.
- Cadas, H., di Tomaso, E., Piomelli, D., 1997. Occurrence and biosynthesis of endogenous cannabinoid precursor. *N*-arachidonoyl phosphatidylethanolamine, in rat brain. *J. Neurosci.* 17, 1226–1242.
- Calignano, A., La Rana, G., Giuffrida, A., Piomelli, D., 1998. Control of pain initiation by endogenous cannabinoids. *Nature* 394, 277–281.
- Collins, D.R., Pertwee, R.G., Davies, S.N., 1994. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. *Eur. J. Pharmacol.* 259, R7–R8.
- Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., Mechoulam, R., 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science* 258, 1946–1949.
- Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.C., Piomelli, D., 1994. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature* 372, 686–691.



- Evans, M.S., Collings, M.A., Brewer, G.J., 1998. Electrophysiology of embryonic, adult and aged rat hippocampal neurons in serum-free culture. *J. Neurosci. Methods* 79, 37–46.
- Farooqui, A.A., Anderson, D.K., Horrocks, L.A., 1993. Effect of glutamate and its analogs on diacylglycerol and monoacylglycerol lipase activities of neuron-enriched cultures. *Brain Res.* 604, 180–184.
- Felder, C.C., Briley, E.M., Axelrod, J., Simpson, J.T., Mackie, K., Devane, W.A., 1993. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. *Proc. Natl. Acad. Sci. U. S. A.* 90, 7656–7660.
- Gammon, C.M., Allen, A.C., Morell, P., 1989. Bradykinin stimulates phosphoinositide hydrolysis and mobilization of arachidonic acid in dorsal root ganglion neurons. *J. Neurochem.* 53, 95–101.
- Giuffrida, A., Piomelli, D., 1998. Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. *FEBS Lett.* 422, 373–376.
- Giuffrida, A., Parsons, L.H., Kerr, T.M., Rodríguez de Fonseca, F., Navarro, M., Piomelli, D., 1999. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. *Nat. Neurosci.* 2, 358–363.
- Hansen, H.S., Lauritzen, L., Strand, A.M., Vinggaard, A.M., Frandsen, A., Schousboe, A., 1997. Characterization of glutamate-induced formation of *N*-acylphosphatidylethanolamine and *N*-acylethanolamine in cultured neocortical neurons. *J. Neurochem.* 69, 753–761.
- Jaggari, S.I., Hasnie, F.S., Sellaturay, S., Rice, A.S., 1998. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. *Pain* 76, 189–199.
- Johnson, J.W., Ascher, P., 1987. Glycine potentiates the NMDA response in cultured mouse brain neurons. *Nature* 325, 529–531.
- Kreitzer, A.C., Reger, W.G., 2001. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. *Neuron* 29, 717–727.
- Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R. et al., 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem. Pharmacol.* 50, 83–90.
- Mechoulam, R., Fride, E., Ben-Shabat, S., Meiri, U., Horowitz, M., 1998. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. *Eur. J. Pharmacol.* 362, R1–R3.
- Misner, D.L., Sullivan, J.M., 1999. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. *J. Neurosci.* 19, 6795–6805.
- Nagayama, T., Sinor, A.D., Simon, R.P., Chen, J., Graham, S.H., Jin, K., Greenberg, D.A., 1999. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. *J. Neurosci.* 19, 2987–2995.
- Nicoletti, F., Wroblewski, J.T., Novelli, A., Alho, H., Guidotti, A., Costa, E., 1986. The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. *J. Neurosci.* 6, 1905–1911.
- Nowak, L., Bregestovski, P., Ascher, P., Herbet, A., Prochiantz, A., 1984. Magnesium gates glutamate-activated channels in mouse central neurones. *Nature* 307, 462–465.
- Ohno-Shosaku, T., Maejima, T., Kano, M., 2001. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. *Neuron* 29, 729–738.
- Pfrieger, F.W., Barres, B.A., 1997. Synaptic efficacy enhanced by glial cells in vitro. *Science* 277, 1684–1687.
- Piomelli, D., Beltramo, M., Giuffrida, A., Stella, N., 1998. Endogenous cannabinoid signaling. *Neurobiol. Dis.* 5, 462–473.
- Piomelli, D., Giuffrida, A., Calignano, A., Rodríguez de Fonseca, F., 2000. The endocannabinoid system as a target for therapeutic drugs. *Trends Pharmacol. Sci.* 21, 218–224.
- Schmid, H.H., 2000. Pathways and mechanisms of *N*-acylethanolamine biosynthesis: can anandamide be generated selectively? *Chem. Phys. Lipids* 108, 71–87.
- Serdarevich, B., 1967. Glyceride isomerizations in lipid chemistry. *JAOCS* 44, 381–393.
- Shen, M., Thayer, S.A., 1999.  $\Delta^9$ -Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. *Mol. Pharmacol.* 55, 8–13.
- Shen, M., Piser, T.M., Seybold, V.S., Thayer, S.A., 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. *J. Neurosci.* 16, 4322–4334.
- Stella, N., Schweitzer, P., Piomelli, D., 1997. A second endogenous cannabinoid that modulates long-term potentiation. *Nature* 388, 773–778.
- Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., Waku, K., 1995. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. *Biochem. Biophys. Res. Commun.* 215, 89–97.
- Sugiura, T., Kodaka, T., Kondo, S., Tonegawa, T., Nakane, S., Kishimoto, S., Yamashita, A., Waku, K., 1996. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free  $Ca^{2+}$  in neuroblastoma × glioma hybrid NG108-15 cells. *Biochem. Biophys. Res. Commun.* 229, 58–64.
- Terranova, J.P., Michaud, J.C., Le Fur, G., Soubrie, P., 1995. Inhibition of long-term potentiation in rat hippocampal slices by anandamide and WIN55212-2: reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 352, 576–579.
- Vogel, Z., Barg, J., Levy, R., Saya, D., Heldman, E., Mechoulam, R., 1993. Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. *J. Neurochem.* 61, 352–355.
- Wilson, R.I., Nicoll, R.A., 2001. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. *Nature* 410, 588–592.